Acadia Pharmaceuticals Inc. (ACAD) intrinsic value & 10-year financials
Acadia Pharmaceuticals Inc. (ACAD) has a Graham intrinsic value of $76.40 per share. At $19.12 on Oct 17, 2026, the stock trades 75% below that value. Over the last 10 fiscal years revenue grew 58.1% a year to $1.1B, with an average return on invested capital of -35.1%.
- Graham intrinsic value
- $76.40
- Share price (Oct 17, 2026)
- $19.12
- Price vs Graham value
- 75% below
- Market cap
- $3.2B
- Revenue (FY2025)
- $1.1B
- Revenue growth (10-yr CAGR)
- 58.1%
- ROIC (10-yr avg)
- -35.1%
- Free cash flow (FY2025)
- $105.1M
ACAD 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.1B | $391.0M | $2.30 | $105.1M | 9.8% | 13.6% |
| FY2024 | $957.8M | $226.5M | $1.36 | $157.2M | 24.1% | 54.3% |
| FY2023 | $726.4M | -$61.3M | -$0.00 | $16.7M | -10.1% | -23.3% |
| FY2022 | $517.2M | -$216.0M | -$0.00 | — | -43.2% | -56.8% |
| FY2021 | $484.1M | -$167.9M | -$0.00 | -$126.8M | -35.2% | -42.9% |
| FY2020 | $441.8M | -$281.6M | -$0.00 | -$143.8M | -64.9% | -66.6% |
| FY2019 | $339.1M | -$235.3M | — | -$152.3M | -72.7% | -47.8% |
| FY2018 | $223.8M | -$245.2M | — | -$169.6M | -110.6% | -60.8% |
| FY2017 | $124.9M | -$289.4M | — | -$218.6M | -234.1% | -68.5% |
| FY2016 | $17.3M | -$271.4M | — | -$209.9M | -1574.1% | -52.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ACADIA PHARMACEUTICALS INC is a consistent compounder, expanding top-line revenue at 58.1% annually over the past decade.
ACADIA PHARMACEUTICALS INC has historically struggled to out-earn its cost of capital, averaging just -24.2% ROIC.
ACADIA PHARMACEUTICALS INC capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, ACADIA PHARMACEUTICALS INC is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $76.40 per share.